{"uid":"cap_IvhlgPLj9ffwHy1YM40t2","slug":"tefferi-2018-gipss-calculator-for-primary-myelofibrosis-965c22b8","name":"Tefferi 2018 GIPSS Calculator for Primary Myelofibrosis","description":"Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.","url":"https://api.magentlab.com/api/calc/gipss","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["karyotype","calr_type1_like","asxl1_mutated","srsf2_mutated","u2af1_q157_mutated"],"properties":{"karyotype":{"enum":["favorable","unfavorable","vhr"],"type":"string","description":"Tefferi 2018 revised three-tier karyotype as assigned by the caller (mutually exclusive). favorable is a normal karyotype or sole 13q−, +9, 20q−, chromosome 1 translocation/duplication, or sex chromosome abnormality including −Y and scores 0. unfavorable is all other abnormalities and scores 1. vhr is very high risk: single/multiple −7, i(17q), inv(3)/3q21, 12p−/12p11.2, 11q−/11q23, +21, or other autosomal trisomies not including +8/+9 and scores 2. magent does not karyotype."},"asxl1_mutated":{"type":"boolean","description":"ASXL1 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence."},"srsf2_mutated":{"type":"boolean","description":"SRSF2 mutation as assigned by the caller (Tefferi 2018). true scores 1. magent does not sequence."},"calr_type1_like":{"type":"boolean","description":"Presence of a type 1/like CALR mutation as assigned by the caller (Tefferi 2018). false (absence) scores 1. true scores 0. Type 2/like CALR, JAK2, MPL, and triple-negative are absence of type 1/like CALR. magent does not sequence."},"u2af1_q157_mutated":{"type":"boolean","description":"U2AF1 Q157 mutation (Q157P or Q157R) as assigned by the caller (Tefferi 2018). true scores 1. U2AF1 S34 does not score. magent does not sequence."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_JeQ1MyihDB-aeI7ZzduM4","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Computes the Genetically Inspired Prognostic Scoring System (GIPSS) risk score and survival category for primary myelofibrosis based on karyotype tier and four somatic mutation flags.","exampleAgentPrompt":"Calculate the GIPSS score for a primary myelofibrosis patient with an unfavorable karyotype, no CALR type 1/like mutation, ASXL1 mutated, SRSF2 mutated, and U2AF1 Q157 not mutated — what risk category and expected median survival does that give?","exampleUseCases":[{"title":"Newly diagnosed PMF risk stratification","prompt":"My patient just diagnosed with primary myelofibrosis has an unfavorable karyotype, no CALR type 1 mutation, ASXL1 is mutated, and SRSF2 and U2AF1 Q157 are both wild-type — can you run the Tefferi 2018 GIPSS and tell me the risk group and expected median survival?"},{"title":"High-risk PMF transplant eligibility assessment","prompt":"I have a PMF patient being considered for allogeneic stem cell transplant: VHR karyotype, CALR type 1 absent, ASXL1 mutated, SRSF2 mutated, U2AF1 Q157 mutated — compute the GIPSS score and 5-year survival estimate so I can document the prognostic basis."},{"title":"Low-risk PMF watchful waiting counseling","prompt":"Can you calculate the GIPSS risk category for a PMF patient with favorable karyotype, CALR type 1/like mutation present, ASXL1 wild-type, SRSF2 wild-type, and U2AF1 Q157 wild-type? I want to confirm this is low risk and get the published median survival to discuss with them."}],"resultDescription":"Returns the numeric GIPSS score (0–6), the corresponding risk category (Low, Intermediate-1, Intermediate-2, or High), and published median and 5-year overall survival estimates from Tefferi 2018 (Low: 26.4 yr / 94%; Int-1: 8.0 yr / 73%; Int-2: 4.2 yr / 40%; High: 2.0 yr / 14%).","failureModes":["Missing required query parameters (karyotype, calr_type1_like, asxl1_mutated, srsf2_mutated, u2af1_q157_mutated) returns a 400 error","Invalid karyotype value outside the enum (favorable/unfavorable/vhr) returns a validation error","Non-boolean values for mutation flags return a schema validation error","Payment not included or insufficient USDC balance returns a 402 Payment Required response"],"whenToPreferThis":"Use this endpoint when you need the Tefferi 2018 GIPSS score specifically — i.e., when cytogenetic and molecular mutation data (CALR type 1, ASXL1, SRSF2, U2AF1 Q157) are already available and you want a purely genetics-driven PMF prognostic score, as distinct from DIPSS (which requires clinical parameters) or MIPSS70-plus (which incorporates additional clinical variables). Prefer this over manual calculation to ensure correct score mapping and published survival lookup.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T18:58:02.835Z","isFirstParty":false}